Encyclopaedia Britannica Announces the Electoral College as 2020 Story of the Year

Kamala Harris, Catherine the Great, and Kobe Bryant on Year in Review List

Chicago, Dec. 10, 2020 (GLOBE NEWSWIRE) — Encyclopaedia Britannica, purveyors of trusted knowledge for over 250 years , has announced its Story of the Year for 2020 along with a roundup of top stories and events that impacted the world. The selection is entirely data-driven and is based on the volume of article views on Britannica.com along with a significant increase in views over the previous year or, in the case of this year’s story, the previous presidential election cycle.  Britannica’s Story of the Year for 2020 is the electoral college.

The electoral college has historically been a hot topic during presidential elections, and this year was no exception.  With controversy and greater scrutiny around various state electoral college votes, views for the United StatesElectoral College Votes by State spiked significantly on November 2, the day before Election Day in America. Interest remained high over the next several days, increasing 31,468% over searches from the 2016 election. As readers looked for more clarity, the article Electoral College increased 16,546% and How Does the Electoral College Work? saw an uptick of 4,568% from the last election.

“The electoral votes were the key to understanding who would win the election—the most important election of our times, as many called it—and they’re part of a complicated historical institution that can be difficult to understand,” says Erik Gregersen, Senior Editor at Encyclopaedia Britannica. “We’re glad that our content could make it all easier to grasp and give our American readers a better sense of how their own votes count and what role they were playing in determining their country’s future.”

Readers also signaled an interest in learning more about the key figures in this year’s election. On November 7, the day President-elect Joe Biden and Vice President-elect Kamala Harris gave their victory speeches, the biography of Kamala Harris saw the greatest one-day article views of any single biography on Britannica.com for the year and was the most popular for any living individual in all of 2020.

Many other stories captivated the world and stood out in the data for 2020. Britannica’s Year in Review sheds light on stories that sent people in droves to Britannica.com for a closer look at the facts behind events and issues shaping the year. In the weeks following the killing of George Floyd by a Minneapolis police officer and the subsequent unrest in the city, readers immersed themselves in learning more  about the history of police brutality in the United States and protests from years before, including the Los Angeles riots of 1992, with a 23,763% increase, and the Harlem race riot of 1935, with a spike of 37,500%.

People also turned to Britannica to learn more about the lives and accomplishments of prominent Americans lost this past year.  Searches for Kobe Bryant spiked after the tragic death of the NBA legend in January, as did the biographies for Supreme Court Justice Ruth Bader Ginsberg and American civil rights leader John Lewis in reaction to their deaths.

In a year of much uncertainty and angst, many looked for ways to decompress and enjoy time spent at home.  Top searches in the world of entertainment include a 7,715% spike for Alexander Hamilton when the Broadway hit was released on Disney+ and a 18,815% increase for Catherine the Great when Hulu debuted The Great, a television series loosely based on the rise of the Empress of Russia.

“What the data shows is that people are turning time and time again to Britannica to put knowledge into context,” says Gregersen.  “Whether they are tuning in to watch Tiger King on Netflix, thinking about how to best protect themselves and their loved ones from the COVID-19 pandemic, or watching the U.S. presidential election unfold, they rely on the facts and trust the credibility of Britannica. In today’s world, Britannica is more relevant than ever.”  

Read more about Britannica’s 2020 Story of the Year and Year in Review.  



About the Britannica Group
The Britannica Group is a global knowledge leader. A pioneer in digital learning since the 1980s, the company today serves the needs of students, lifelong learners, and professionals by providing curriculum products, language-study courses, digital encyclopedias, and professional readiness training through its extensive products.

The company has continued to redefine information discovery in the technology and education fields, serving 83 countries and 150 million students worldwide in 16 languages. Britannica’s mission to inspire curiosity and the joy of learning has earned it the ranking of the #1 company to watch in EdTech Digest’s State of the EdTech report for 2019-2020. It is headquartered in Chicago.

For more information, visit corporate.britannica.com and follow @Britannica on Facebook, Twitter, and Instagram.


er, and Instagram.

Meghan Lunghi
Encyclopedia Britannica
[email protected]

Scotiabank Announces Sponsorship with the Professional Women’s Hockey Players Association (PWHPA)

Canada NewsWire

Scotiabank furthers support of women’s equality and inclusion in ice hockey

CALGARY, AB, Dec. 10, 2020 /CNW/ – Scotiabank, in partnership with the Professional Women’s Hockey Players Association (PWHPA), today announced its entry to the 2021 Secret® Dream Gap Tour. Players based in Calgary will officially be part of Team Scotiabank, and will compete against four additional PWHPA teams for the Secret® Cup.

Scotiabank is the Official Bank of the PWHPA and supports their goal of showcasing the most talented women hockey players in the world.

“We are proud to support the PWHPA and their efforts towards making ice hockey more inclusive for women,” says Laura Curtis Ferrera, Chief Marketing Officer at Scotiabank. “At Scotiabank, we believe diversity makes us stronger. That’s why we’re committed to making sure hockey is welcoming and accessible to all players, no matter their gender. When we do this, young girls from all backgrounds can go on to inspire future generations of players and build a more inclusive game.”

The PWHPA will announce dates for The Tour early next year and will adhere to all provincial and federal legislation surrounding the COVID-19 pandemic. All pertinent information relating to the tour will be shared via pwhpa.com.

“Sponsors such as Scotiabank are making it possible for women and young girls to pursue their dreams and achieve success at the highest level possible,” says PWHPA player Brigette Lacquette. “I am beyond grateful for all the sponsors who support the PWHPA and am proud to be part of Team Scotiabank.”

Scotiabank and the PWHPA are also collaborating on a mentorship program for young female players that is scheduled to launch in the new year.

“The PWHPA is thrilled to welcome Scotiabank to our team of incredible partners who continue to stand with us, and advocate for the creation of a viable and sustainable professional women’s hockey league,” says PWHPA Operations Consultant Jayna Hefford. “Scotiabank has committed to supporting hockey at all levels across the country, and we are excited to help grow the women’s game alongside them.”

Often referred to as Canada’s Hockey Bank, Scotiabank has a long history of supporting girls and women in hockey, as evidenced by the following initiatives:

  • Scotiabank Girls HockeyFest – a national program that offers on- and off-ice skills training, advice and encouragement from elite athletes – has engaged more than 4,200 girls since 2006.
  • Scotiabank Hockey Day in Canada – a cross-country hockey celebration established in 2011 – regularly features PWHPA players, like Jamie Lee Rattray and Ann-Sophie Bettez.
  • The Scotiabank Skaters Contest, which gives children across the country a once-in-a-lifetime chance to join their hockey heroes on the ice.
  • Sponsor of the 2021 IIHF Women’s World Championship via our partnership with Hockey Canada.
  • Supported the Canadian Women’s Hockey League (CWHL) for over a decade, which featured the most talented players in the women’s game.
  • Scotiabank’s Hockey 24 documentary – A Film By Canada – highlights the importance of the sport at all levels and includes the PWHPA’s Jayna Hefford and Scotiabank Teammate Natalie Spooner.

Scotiabank is also pleased to announce that one of Canada’s greatest female hockey players –Cassie Campbell-Pascall – will continue as a Scotiabank Teammate. Scotiabank Teammates act as ambassadors at events throughout the year and are featured in Scotiabank’s marketing campaigns. She is a passionate ambassador, who works tirelessly to help grow the game of hockey for women and girls, while promoting the importance of diversity and inclusion in the sport.

About Professional Women’s Hockey Players Association (PWHPA)

Professional Women’s Hockey Players Association’s (PWHPA) mission is to promote, advance and support a single, viable professional women’s ice hockey league in North America that showcases the greatest product of women’s professional ice hockey in the world. The organization aims to prove a united voice to players advocating for the creation of a sustainable professional league. Comprised of the world’s best female hockey players including 38 Olympians, 60+ members of Hockey Canada and USA Hockey, and National Champions for Canada, USA, Finland and Russia. PWHPA is working to accomplish its mission by coordinating training needs and programming opportunities during the 2020-2021 season and collaborating with like-minded organizations to make hockey more inclusive for women today and for future generations. To learn more about PWHPA and the Dream Gap tour visit www.pwhpa.com.

About Scotiabank

Scotiabank is a leading bank in the Americas. Guided by our purpose: “for every future”, we help our customers, their families and their communities achieve success through a broad range of advice, products and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. With a team of over 90,000 employees and assets of approximately $1.1 trillion (as at October 31, 2020), Scotiabank trades on the Toronto Stock Exchange (TSX: BNS) and New York Stock Exchange (NYSE: BNS). For more information, please visit http://www.scotiabank.com and follow us on Twitter @ScotiabankViews.

SOURCE Scotiabank

Protagonist Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

PR Newswire

NEWARK, Calif., Dec. 10, 2020 /PRNewswire/ — Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of $100,000,000 of shares of its common stock. All of the shares of common stock are being offered by Protagonist. In connection with this offering, Protagonist expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the public offering.

J.P. Morgan Securities LLC, SVB Leerink LLC, Piper Sandler & Co. and BMO Capital Markets Corp. are acting as joint book-running managers for the offering. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed or the actual size or terms of the offering.

A shelf registration statement relating to the offered shares of common stock was filed with the Securities and Exchange Commission (SEC) on December 10, 2020. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website, located at www.sec.gov. Prospective investors should read the preliminary prospectus supplement, when available, and the accompanying prospectus and other documents Protagonist has filed with the SEC for more complete information about Protagonist and the offering. Copies of the prospectus supplement and the accompanying prospectus related to the offering may be obtained, when available, from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204 or by email at [email protected];  from SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, ext. 6132 or by email at [email protected]; from Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924 or by email at [email protected]; or from BMO Capital Markets Corp., Attn: Equity Syndicate Department, 3 Times Square, 25th Floor, New York, NY 10036, tel: (800) 414-3627, email: [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding Protagonist’s expectations regarding the completion, timing and size of the proposed public offering. In some cases, you can identify these statements by forward-looking words such as “expect,” “may,” “will,”  or the negative or plural of these words or similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). These forward-looking statements are based on Protagonist’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. These risks and uncertainties include, without limitation, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the proposed public offering. There can be no assurance that Protagonist will be able to complete the proposed public offering on the anticipated terms, or at all. Additional information concerning these and other risks can be found in Protagonist’s periodic filings with the U.S. Securities and Exchange Commission, including under the heading “Risk Factors” contained therein, as well as the risks identified in the registration statement and the preliminary prospectus supplement relating to the offering. Any forward-looking statements that Protagonist makes in this press release speak only as of the date of this press release. Except as required by law, Protagonist assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.


Cision View original content:http://www.prnewswire.com/news-releases/protagonist-therapeutics-inc-announces-proposed-public-offering-of-common-stock-301190335.html

SOURCE Protagonist Therapeutics, Inc.

CME Group Declares Annual Variable Dividend

PR Newswire

CHICAGO, Dec. 10, 2020 /PRNewswire/ — CME Group Inc., the world’s leading and most diverse derivatives marketplace, today declared its annual variable dividend, amounting to $2.50 per share. The dividend is payable January 13, 2021, to shareholders of record on December 28, 2020.

The annual variable dividend of $2.50 per share to be paid in January 2021 totals approximately $900 million. Including today’s announced variable dividend and the previously announced fourth-quarter 2020 dividend of $0.85 per share to be paid in December, the total dividend yield for dividends announced during 2020 is 3.3% based on the average closing stock price in 2020 to date. The company will have paid a total of more than $15 billion in quarterly and variable dividends since adopting the annual variable dividend structure in the beginning of 2012. 

When CME Group adopted its annual variable dividend structure in February 2012, the intention was to determine the excess cash available at the end of each year, with the level to increase or decrease from year to year based on operating results, potential investment activity and other forms of capital return.  

As the world’s leading and most diverse derivatives marketplace, CME Group (www.cmegroup.com) enables clients to trade futures, options, cash and OTC markets, optimize portfolios, and analyze data – empowering market participants worldwide to efficiently manage risk and capture opportunities. CME Group exchanges offer the widest range of global benchmark products across all major asset classes based on interest ratesequity indexesforeign exchangeenergyagricultural products and metals.  The company offers futures and options on futures trading through the CME Globex® platform, fixed income trading via BrokerTec and foreign exchange trading on the EBS platform. In addition, it operates one of the world’s leading central counterparty clearing providers, CME Clearing. With a range of pre- and post-trade products and services underpinning the entire lifecycle of a trade, CME Group also offers optimization and reconciliation services through TriOptima, and trade processing services through Traiana.

CME Group, the Globe logo, CME, Chicago Mercantile Exchange, Globex, and, E-mini are trademarks of Chicago Mercantile Exchange Inc.  CBOT and Chicago Board of Trade are trademarks of Board of Trade of the City of Chicago, Inc.  NYMEX, New York Mercantile Exchange and ClearPort are trademarks of New York Mercantile Exchange, Inc.  COMEX is a trademark of Commodity Exchange, Inc. BrokerTec, EBS, TriOptima, and Traiana are trademarks of BrokerTec Europe LTD, EBS Group LTD, TriOptima AB, and Traiana, Inc., respectively. Dow Jones, Dow Jones Industrial Average, S&P 500 and S&P are service and/or trademarks of Dow Jones Trademark Holdings LLC, Standard & Poor’s Financial Services LLC and S&P/Dow Jones Indices LLC, as the case may be, and have been licensed for use by Chicago Mercantile Exchange Inc.  All other trademarks are the property of their respective owners. 


Cision View original content:http://www.prnewswire.com/news-releases/cme-group-declares-annual-variable-dividend-301190219.html


BioSteel Inks Partnership with Toronto Raptors as Official Sports Drink

PR Newswire

The multi-year partnership makes BioSteel the official sports drink of the Toronto Raptors team, and presenting partner of Raptors Training Camp

NEW YORK, Dec. 10, 2020 /PRNewswire/ – BioSteel today announced a multi-year deal with the Toronto Raptors as the team’s official sports drink partner. The partnership designates the sports hydration company as the official sports drink of the team and presenting partner of Raptors Training Camp, which began earlier this week in Tampa, FL.

“The Raptors have been purchasing BioSteel products since day one,” said Michael Cammalleri, Co-Founder and Co-CEO, BioSteel. “With this alliance, BioSteel has the opportunity to hydrate Canada’s NBA team and we’re thrilled that they have chosen to partner with a sugar-free sports drink company.”

The multi-year partnership will make BioSteel’s new sugar-free sports drink in an eco-friendly tetra pak available to players on the sidelines. The deal also includes prominent BioSteel branding at all Raptors home games, in addition to branding at the team’s training facility in Toronto. BioSteel’s logo will be seen on coolers, cups, and on sidelines and bench areas, home and visiting team chair backs, courtside LEDs and pole pad signage.  BioSteel’s sports drink will be available in all sideline coolers and locker rooms.

“With the help of BioSteel, our athletes will stay hydrated with products that put health and wellness first, and play at the highest level,” said Jordan Vader, Vice President, Global Partnerships & Retail, MLSE. “It is this commitment to sport hydration and performance that we share with this leading organization in the sport drink industry, during a season that our fans will never forget.”

BioSteel was founded in 2009 with a focus on all-natural, sugar-free, and nutritious products. This year, BioSteel has rolled out a ready-to-drink electrolyte-packed sports drink in eco-friendly tetra paks, in a range of flavors. Trusted by top professional athletes globally, BioSteel’s premium sugar-free sports drink has been designed in the most natural way possible.

Originally formulated for professional athletes, BioSteel’s products have gained popularity amongst consumers due to the authenticity of the brand’s partnerships and the quality and efficacy of its products. This relationship allows BioSteel to continue to tell its authentic story that started in the locker room and is now entering into the mass retail market as it expands through the brand’s recently signed distribution agreements.

For more information on where to purchase BioSteel’s new sports drink, please visit biosteel.com.

About BioSteel
BioSteel is a North American operated sports hydration company that was built on the mandate of providing the safest, healthiest, and most effective line of nutritional products available. BioSteel products are currently readily available across North America, and globally with select retail partners or direct to consumers online, through www.biosteel.com.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/biosteel-inks-partnership-with-toronto-raptors-as-official-sports-drink-301189941.html

SOURCE BioSteel Sports Nutrition Inc.

Cigna Announces Leadership Changes to Accelerate Next Phase of Growth

– Eric Palmer becomes president and chief operating officer of Evernorth

– Brian Evanko becomes chief financial officer of Cigna Corporation

– Matt Manders assumes leadership of government business as president, government and solutions of Cigna Corporation

– Everett Neville promoted to executive vice president, strategy and business development of Cigna Corporation

– Aparna Abburi promoted to president, Medicare

– Amy Bricker promoted to president, Express Scripts

PR Newswire

BLOOMFIELD, Conn., Dec. 10, 2020 /PRNewswire/ — Cigna Corporation (NYSE: CI) today announced leadership changes designed to accelerate the company’s growth through its two power brands, Cigna and Evernorth. Effective Jan. 1, 2021, Eric Palmer will become the president and chief operating officer of Evernorth; Brian Evanko will become executive vice president and chief financial officer of Cigna Corporation; Matt Manders will assume the role of president, government and solutions of Cigna Corporation; Everett Neville will assume the role of executive vice president, strategy and business development of Cigna Corporation; Aparna Abburi will assume the role of president, Medicare; and Amy Bricker will assume the role of president, Express Scripts.

“The depth and breadth of our leadership talent are a key strength of our organization,” said David M. Cordani, president and chief executive officer, Cigna Corporation. “These leaders have a track record of driving growth, and a relentless focus on supporting the diverse needs of all those we serve around the world by delivering on our promise of making health care more affordable, predictable, and simple. I am pleased that our long-standing commitment to talent development allows us to strategically place our seasoned team of leaders in key positions that will maximize value-creation and value-generation for our customers, clients, and shareholders.”

Eric Palmer named president and chief operating officer of Evernorth

Palmer has been named president and chief operating officer of Evernorth. In this new role, Palmer will have oversight of Evernorth’s pharmacy services, care management services and benefit management services. He will remain a member of Cigna Corporation’s enterprise leadership team, and will report to Tim Wentworth, chief executive officer of Evernorth.

Palmer joined the company in 1998, and currently serves as chief financial officer. Over the course of his more than 22 years at Cigna, Palmer has held multiple key finance and actuarial leadership roles, and contributed to the success of the combination of Cigna and Express Scripts, as well as the launch of Evernorth. Palmer’s market perspective, deep business experience and focus on value creation make him uniquely suited to lead Evernorth operations through its new and exciting chapter of growth.

Brian Evanko named executive vice president and chief financial officer of Cigna

Evanko has been named the new chief financial officer of Cigna Corporation. As CFO, Evanko will assume leadership for all of Cigna Corporation’s financial operations and functions, including the company’s investment management and underwriting units. He will continue to report to David Cordani

Evanko joined Cigna in 1998, and currently serves as president, government business, where he led the growth strategy for each of its businesses. Evanko has held multiple key leadership roles over the span of his 22-year Cigna career, including serving as business financial officer for Cigna’s global individual operations.

Matt Manders assumes oversight of government business

Manders is assuming an expanded leadership role as president, government and solutions for Cigna Corporation. In addition to oversight of Cigna Solutions, Manders will lead Cigna’s U.S. government business segment, including all Medicare, Individual, and Medicaid product offerings.

Over his 30-year career with Cigna, Manders has served in a variety of key commercial and strategic leadership roles in the U.S. and abroad, including previously serving as president, government and individual programs. His experience at the helm of multiple Cigna businesses and functions will support the continued rapid growth of the government businesses.

Everett Neville named executive vice president, strategy and business development

Neville has been named executive vice president, strategy and business development. In this new role, Neville will have oversight of Cigna Corporation’s strategy, corporate development, business development, and Cigna Ventures. Reporting to David Cordani, he will become a member of Cigna Corporation’s enterprise leadership team.

A pharmacist by training, Neville joined Cigna’s Express Scripts business in 1998. He most recently served as senior vice president, value creation for Cigna Corporation. Over the span of his career with Express Scripts, he held leadership roles in supply chain and in the health plan division.

Aparna Abburi promoted to president, Medicare business

Abburi has been named president, Medicare.  In this role, Abburi will continue leading Cigna’s Medicare Advantage business, and will also assume oversight of Cigna Supplemental Benefits and Government Pharmacy. 

Abburi joined Cigna in July, 2020, from Health Care Services Corporation (HCSC), where she served as president of the Medicare business. 

Amy Bricker promoted to president, Express Scripts business

Bricker has been named president, Express Scripts. Bricker’s responsibilities will expand from leading supply chain and drug procurement, to leadership for all of Evernorth’s pharmacy benefit management (PBM) services. 

Over the past decade with Express Scripts, Bricker, a pharmacist by training, has served in a variety of key leadership roles in pharmacy network management, supply chain economics, and retail contracting and strategy.

About Cigna

Cigna Corporation is a global health service company dedicated to improving the health, well-being and peace of mind of those we serve. Cigna delivers choice, predictability, affordability and access to quality care through integrated capabilities and connected, personalized solutions that advance whole person health. All products and services are provided exclusively by or through operating subsidiaries of Cigna Corporation, including Cigna Health and Life Insurance Company, Cigna Life Insurance Company of New York, Connecticut General Life Insurance Company, Evernorth companies or their affiliates, Express Scripts companies or their affiliates, and Life Insurance Company of North America. Such products and services include an integrated suite of health services, such as medical, dental, behavioral health, pharmacy, vision, supplemental benefits, and other related products. Cigna maintains sales capability in over 30 countries and jurisdictions, and has approximately 190 million customer relationships throughout the world. To learn more about Cigna®, including links to follow us on Facebook or Twitter, visit www.cigna.com.

About Evernorth

Evernorth is the brand for Cigna’s growing, high-performing health services portfolio. The Evernorth brand is anchored by Evernorth Health, Inc., a wholly-owned subsidiary of Cigna Corporation, and the parent company of the Express Scripts, Accredo, and eviCore companies. Evernorth brings together and coordinates premier health services offerings to deliver innovative and flexible solutions for health plans, employers, and government programs. All Evernorth solutions are serviced and provided by or through operating affiliates of Evernorth Health or third-party partners. To learn more about Evernorth, visit www.Evernorth.com.

Media Contact

Jim Cohn

[email protected]


Investor Relations Contact

Alexis Jones

[email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cigna-announces-leadership-changes-to-accelerate-next-phase-of-growth-301190013.html


Former Seattle Police Chief to Join Axon’s AI Ethics Board, Promoting Responsible Development of AI Technologies

Chief Carmen Best joins board to ensure the advancement of ethical AI technology in law enforcement

PR Newswire

SEATTLE, Dec. 10, 2020 /PRNewswire/ — Axon (Nasdaq: AAXN), the global leader in connected public safety technologies, today announced the appointment of Carmen Best, former Seattle police chief, to Axon’s AI Ethics Board.

“I admire Axon’s commitment to developing ethical AI technologies, especially examining how it impacts communities of color,” says Chief Best, who rose through the ranks through a nearly 30-year policing career to become the first black woman to lead Seattle’s police force. “I support the responsible development and deployment of AI technologies to improve community safety and improve how police work with communities.”

Best holds a distinguished career of public safety and transparency within Seattle’s Police department. As chief of police, Best championed diversity reforms, public safety, and gender equality. She fostered record-breaking women and diversity hiring and recruitment and is widely recognized for her dedication to justice and community. In addition to her service to Seattle’s communities, she is also a U.S. Army veteran, having served three years in South Korea.

Axon is proud to be developing products that address some of society’s most entrenched problems. As a leading technology company for law enforcement, Axon believes it has the obligation to do so in a responsible way — one that promotes transparency, with built in mechanisms for accountability. Axon’s AI and Policing Technology Ethics Board provides expert guidance to Axon on the development of its AI products and services, paying particular attention to its impact on communities. This diverse board includes leaders in the industry as well as some of the nation’s most well-known thought leaders and legal scholars regarding policing, police reform, technology, racial equity and civil liberties.

For more information on the AI and Policing Technology Ethics Board, please visit: www.axon.com/ethics.

About Axon

Axon is a network of devices, apps and people that helps public safety personnel become smarter and safer. With a mission of protecting life, our technologies give customers the confidence, focus and time they need to keep their communities safe. Our products impact every aspect of a public safety officer’s day-to-day experience.

We work hard for those who put themselves in harm’s way for all of us. To date, there are more than 300,000 software seats booked on the Axon network around the world and more than 242,000 lives and countless dollars have been saved with the Axon network of devices, apps, and people. Learn more at www.axon.com or by calling (800) 978-2737.

Facebook is a trademark of Facebook, Inc., and Twitter is a trademark of Twitter, Inc. Axon, and the Delta Logo are trademarks of Axon Enterprise, Inc., some of which are registered in the US and other countries. For more information, visit www.axon.com/legal. All rights reserved.

Follow Axon here:

Note to Investors

Please visit http://investor.axon.com, https://www.axon.com/press, www.twitter.com/axon_us and https://www.facebook.com/Axon.ProtectLife/ where Axon discloses information about the company, its financial information and its business.

Visit our Investor Relations Safe Harbor Statement at: http://investor.axon.com/safeHarbor.cfm


Sydney Siegmeth

VP, Global Communications
[email protected]


Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/former-seattle-police-chief-to-join-axons-ai-ethics-board-promoting-responsible-development-of-ai-technologies-301190202.html


First Patient Enrolled in Novocure’s Global Phase 3 TRIDENT Trial of Optune® Concurrent with Radiation Therapy in Newly Diagnosed Glioblastoma

First Patient Enrolled in Novocure’s Global Phase 3 TRIDENT Trial of Optune® Concurrent with Radiation Therapy in Newly Diagnosed Glioblastoma

TRIDENT will test the potential survival benefit of initiating Optune concurrent with radiation therapy in patients with newly diagnosed glioblastoma

Preclinical studies demonstrate that Tumor Treating Fields increase sensitivity to radiation therapy and inhibit DNA damage repair

Novocure (NASDAQ: NVCR) today announced the first patient has been enrolled in its global phase 3 TRIDENT trial, a randomized study in newly diagnosed glioblastoma (GBM) testing the potential survival benefit of initiating Optune concurrent with radiation therapy.

Currently, Optune with maintenance temozolomide is used to treat adults with glioblastoma, following maximal debulking surgery and completion of radiation therapy. However, preclinical studies demonstrate Tumor Treating Fields can be used synergistically with radiation therapy, due to increased tumor sensitivity to radiation therapy, further inhibiting DNA damage repair.

Trident will enroll 950 newly diagnosed GBM patients who, after surgery or biopsy, are candidates for radiation therapy and temozolomide. The experimental group will receive Optune concurrent with radiation therapy and temozolomide for six weeks, followed by Optune and temozolomide. The control group will receive radiation therapy and temozolomide for six weeks, followed by Optune and temozolomide. Patients will continue on Optune for 24 months or until second tumor progression, whichever occurs first.

“We are excited to have begun our TRIDENT trial in newly diagnosed GBM,” said Dr. Ely Benaim, Novocure’s Chief Medical Officer. “The TRIDENT trial represents our commitment to extending survival for GBM patients. We look forward to our partnership with the hundreds of patients who will participate in this study, their families and caregivers, and the nearly 100 leading institutions who have committed to this important research in GBM.”

About Optune

Optune is a noninvasive, antimitotic cancer treatment for GBM. Optune delivers Tumor Treating Fields to the region of the tumor.

Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division. Tumor Treating Fields does not stimulate or heat tissue and targets dividing cancer cells with specific membrane properties. Tumor Treating Fields causes minimal damage to healthy cells. Mild to moderate skin irritation is the most common side effect reported. Tumor Treating Fields is approved in certain countries for the treatment of adults with GBM and in the U.S. for MPM, two of the most difficult cancer types to treat. The therapy shows promise in multiple solid tumor types – including some of the most aggressive forms of cancer.

Approved Indications

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).

Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery, and completion of radiation therapy together with concomitant standard of care chemotherapy.

For the treatment of recurrent GBM, Optune is indicated following histologically- or radiologically-confirmed recurrence in the supratentorial region of the brain after receiving chemotherapy. The device is intended to be used as a monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.

Important Safety Information


Do not use Optune in patients with GBM with an implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render Optune ineffective.

Use of Optune for GBM together with implanted electronic devices has not been tested and may lead to malfunctioning of the implanted device.

Do not use Optune for GBM in patients known to be sensitive to conductive hydrogels. Skin contact with the gel used with Optune may commonly cause increased redness and itching, and may rarely lead to severe allergic reactions such as shock and respiratory failure.

Warnings and Precautions

Optune can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure®.

The most common (≥10%) adverse events involving Optune in combination with chemotherapy in patients with GBM were thrombocytopenia, nausea, constipation, vomiting, fatigue, convulsions, and depression.

The most common (≥10%) adverse events related to Optune treatment alone in patients with GBM were medical device site reaction and headache. Other less common adverse reactions were malaise, muscle twitching, and falls related to carrying the device.

If the patient has an underlying serious skin condition on the treated area, evaluate whether this may prevent or temporarily interfere with Optune treatment.

Do not prescribe Optune for patients that are pregnant, you think might be pregnant or are trying to get pregnant, as the safety and effectiveness of Optune in these populations have not been established.

About Novocure

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Tumor Treating Fields is a cancer therapy that uses electric fields to disrupt cancer cell division. Novocure’s commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer.

Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Additionally, the company has offices in Germany, Switzerland, Japan and Israel. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure.

Forward-Looking Statements

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as issues arising from the COVID-19 pandemic and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 27, 2020 and its Quarterly Report on Form 10-Q filed on April 30, 2020, as amended to date, with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.


Gabrielle Fernandes

[email protected]



Jaclyn Stahl

[email protected]


KEYWORDS: Jersey Europe

INDUSTRY KEYWORDS: Research Medical Devices FDA Clinical Trials Biotechnology Radiology Pharmaceutical Health Science Oncology



Temas Resources Announces Closing of $2.6 Million Flow-Through Financing at $1.00 per Share

Temas Resources Announces Closing of $2.6 Million Flow-Through Financing at $1.00 per Share

Laurentian Bank Securities Inc. acts as advisor to Temas Resources

Temas Resources Corp. (the “Company” or “Temas Resources”, CSE: TMAS, OTCQB: TMASF), a publicly traded company focused on the advancement of mineral independence within stable, mining-friendly jurisdictions, announced today it has closed a private placement of 2,625,000 flow-through common shares (the “Shares”) at a price of $1.00 per Share for gross proceeds $2.625 million.

“Laurentian Bank Securities Inc.’ support of Temas Resources in the closing of this private placement at such a significant premium to the current share price confirms to us the market’s confidence in our company’s direction,” said Michael Dehn, CEO. “This $2.625 million financing is invaluable early-stage reinforcement of Temas Resources’ ability to achieve critical mining exploration objectives and execute on the vision and strategy we’ve put forth to date.”

The Private Placement is for an aggregate amount of CAD$2.625 million priced at $1.00 per Share. The Company intends to utilize the proceeds for mining exploration purposes in the province of Québec within 24 months.

“This Private Placement through Laurentian Bank Securities Inc. adds additional certainty to Temas Resources’ current corporate trajectory. The consistent support we’re beginning to see from financial institutions is allowing Temas Resources to continue to accelerate its rate of development,” Michael Dehn continued. “We appreciate the vote of confidence shown in the Private Placement market valuation of $1.00 per share, affirming we are taking Temas Resources’ leadership, mission, and ongoing operations in the right direction.”

Temas Resources has paid Laurentian Bank Securities Inc. (“Laurentian Bank”) a cash finder’s fee in an amount equal to 7% of the gross proceeds of the Private Placement. In addition, Temas Resources has issued non-transferable share purchase warrants priced at $1.00 equal to 7% of the aggregate number of Shares purchased to Laurentian Bank.

About Laurentian Bank Securities Inc.

Laurentian Bank Securities Inc. is an integrated full-service investment dealer, focusing on six lines of business. The well-respected Institutional fixed income division has a strong presence in Government and Corporate underwritings, as well as in secondary markets. In addition, the Institutional equity division focuses on serving clients through research, trading and investment banking in the small capitalization sector. The fast-growing Retail division and Discount Brokerage division currently serve clients through 13 offices in Québec. Furthermore, as a carrying broker, LBS provides complete back office support to a wide range of customers. LBS also offers the Immigrant Investors program. In the institutional market as in the retail market, Laurentian Bank Securities Inc. places above all, its expertise, experience, and sense of innovation to ensure its position and bring added-value to all of its activities.

About Temas Resources

Temas Resources Corp. (“Temas Resources“) (CSE: TMAS) (OTCQB: TMASF) is responding to the growing global demand for iron ore and two strategically important minerals — titanium and vanadium — deemed by the U.S. Department of the Interior as critical to U.S. national security and the economy. Temas Resources properties are located in the stable, mining-friendly jurisdiction of Quebec (Canada) bordering Vermont, Maine, and New York State (U.S.) in an area known as the Grenville Geological Province. The Grenville Geological Province is home to Lac Tio, the largest solid ilmenite deposit in the world. As a mineral exploration company focused on the acquisition, exploration and development of iron, titanium, and vanadium properties, Temas Resources has focused its efforts on advancing two major projects in the Grenville Geological Province area. The Company’s first project, the DAB Property, consists of an option for 100% interest on 128 contiguous mineral claims which covers 6,813 hectares (68.14 km²) within the Grenville Geological Province. At the Company’s flagship La Blache Property, Temas has 100% ownership of 48 semi-contiguous mineral claims which cover 2,653 hectares (26.53 km²) within the Grenville Geological Province. All public filings for the Company can be found on the SEDAR website www.sedar.com. For more information about the Company, please visit www.temasresources.com.

On behalf of the Board of Directors of Temas Resources Corp.,

“Kyler Hardy”


Forward Looking Statements

This news release includes certain “Forward‐Looking Statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward‐looking information” under applicable Canadian securities laws. When used in this news release, the words “anticipate”, “believe”, “estimate”, “expect”, “target”, “plan”, “forecast”, “may”, “would”, “could”, “schedule” and similar words or expressions, identify forward‐looking statements or information.

Forward‐looking statements and forward‐looking information relating to any future mineral production, liquidity, enhanced value and capital markets profile of Temas Resources, future growth potential for Temas Resources and its business, and future exploration plans are based on management’s reasonable assumptions, estimates, expectations, analyses and opinions, which are based on management’s experience and perception of trends, current conditions and expected developments, and other factors that management believes are relevant and reasonable in the circumstances, but which may prove to be incorrect. Assumptions have been made regarding, among other things, the price of iron, titanium, vanadium and other metals; no escalation in the severity of the COVID-19 pandemic; costs of exploration and development; the estimated costs of development of exploration projects; Temas Resources’ ability to operate in a safe and effective manner and its ability to obtain financing on reasonable terms.

These statements reflect Temas Resources’ respective current views with respect to future events and are necessarily based upon a number of other assumptions and estimates that, while considered reasonable by management, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward‐looking statements or forward-looking information and Temas Resources has made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation: the Company’s dependence on one mineral project; precious metals price volatility; risks associated with the conduct of the Company’s mining activities in Quebec; regulatory, consent or permitting delays; risks relating to reliance on the Company’s management team and outside contractors; risks regarding mineral resources and reserves; the Company’s inability to obtain insurance to cover all risks, on a commercially reasonable basis or at all; currency fluctuations; risks regarding the failure to generate sufficient cash flow from operations; risks relating to project financing and equity issuances; risks and unknowns inherent in all mining projects, including the inaccuracy of reserves and resources, metallurgical recoveries and capital and operating costs of such projects; contests over title to properties, particularly title to undeveloped properties; laws and regulations governing the environment, health and safety; the ability of the communities in which the Company operates to manage and cope with the implications of COVID-19; the economic and financial implications of COVID-19 to the Company; operating or technical difficulties in connection with mining or development activities; employee relations, labour unrest or unavailability; the Company’s interactions with surrounding communities and artisanal miners; the Company’s ability to successfully integrate acquired assets; the speculative nature of exploration and development, including the risks of diminishing quantities or grades of reserves; stock market volatility; conflicts of interest among certain directors and officers; lack of liquidity for shareholders of the Company; litigation risk; and the factors identified under the caption “Risk Factors” in Temas Resources’ management discussion and analysis. Readers are cautioned against attributing undue certainty to forward‐looking statements or forward-looking information. Although Temas Resources has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be anticipated, estimated or intended. Temas Resources does not intend, and does not assume any obligation, to update these forward‐looking statements or forward-looking information to reflect changes in assumptions or changes in circumstances or any other events affecting such statements or information, other than as required by applicable law.

Nick Spencer, Investor Relations

Phone: +1 (604) 332-0902

Email: [email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Mining/Minerals Natural Resources


Tenet to Acquire Portfolio of Surgery Centers from SurgCenter Development

Tenet to Acquire Portfolio of Surgery Centers from SurgCenter Development

Expands USPI ambulatory business in line with Tenet’s stated strategy

Addition of up to 45 SCD centers cements Tenet’s position as preeminent national musculoskeletal services leader across care continuum

Investment in lower cost of care, highly efficient, consumer-friendly facilities that improve healthcare affordability and access

Enhances Tenet’s overall business mix and earnings profile

Management will host a conference call today, Dec. 10, at 8:30 a.m. Eastern Time, to discuss the transaction

Tenet Healthcare Corporation (NYSE: THC) today announced that it will acquire a portfolio of up to 45 ambulatory surgery centers (ASCs) (the “Portfolio”) from SurgCenter Development (SCD). The Portfolio will be operated by Tenet’s United Surgical Partners International (USPI) subsidiary as part of its industry-leading ambulatory surgery platform.

SCD, founded in 1993, is a leading developer of physician-owned ASCs with a history of establishing high-quality centers in partnership with physicians with demonstrated leadership in musculoskeletal surgeries. The 45 centers are located in Arizona, Florida, Indiana, Louisiana, Maryland, Ohio, New Hampshire, Texas and Wisconsin.

Under the terms of the transaction, the Company will purchase majority interests in up to 45 centers by fully acquiring SCD’s interests, and partially acquiring interests from physician partners, for approximately $1.1 billion in cash and the assumption of approximately $18 million of center-level debt.

USPI’s ownership interest will be up to 60 percent in each center, with the remainder owned by physician partners. Tenet will consolidate the financial results of the Portfolio within its Ambulatory Care segment with the exception of two centers in which USPI will own a minority interest. Tenet has completed the acquisition of a majority of the 45 centers and expects to complete the acquisition of the remainder of the Portfolio by the end of 2020, pending the finalization of documentation and the receipt of certain state approvals.

Ron Rittenmeyer, Tenet’s Executive Chairman and CEO, said, “This is a transformative transaction within our stated strategy to expand our ambulatory platform. It will enhance our overall business mix and further diversify our earnings profile by accelerating our shift toward lower cost of care, consumer-friendly, faster-growing assets for Tenet, USPI and our physician and health system partners. The transaction is a testament to the caliber and quality of the SCD facilities, physicians and staff, USPI’s incredible performance, and both organizations’ quick recovery relative to the pandemic.”

Dr. Gregory George, Co-Founder of SurgCenter, stated, “SCD is very pleased to complete this transaction with USPI, marking another milestone in our longstanding relationship. Following prior transactions with USPI, we consistently received strong positive feedback from our former physician partners who subsequently worked with USPI to continue to build and grow partnerships that we had developed together. The history between the companies made this transaction a natural evolution for many of our current physician partners and their facilities, enabling them to leverage the breadth and depth of both USPI and Tenet. We look forward to seeing the further growth and success of these partnerships while we continue to focus on the development of additional de novo facilities.”

Brett Brodnax, USPI’s President and CEO, said, “We acquired our first ASCs from SCD in 2005 and have built a longstanding and successful relationship. We have a tremendous amount of respect for SCD as one of the leading developers of ambulatory surgical facilities in the country. We are honored to be partnering with the high-quality physicians and staff who have an excellent track record of delivering patient-centered care with great outcomes in the communities they serve. The Portfolio will be an excellent complement to our national footprint of ambulatory surgical facilities, and we expect a seamless integration.”

Strategic Benefits of the Transaction

Creates largest musculoskeletal (“MSK”) surgery platform with national scale. Through the transaction, Tenet will become the leading provider of high-growth MSK surgeries across the care continuum, far surpassing others in the sector. Pending completion of the transaction, USPI’s surgical portfolio will have as many as 310 ambulatory surgical facilities, including 24 surgical hospitals, in 33 states. It will expand USPI’s established footprint in high-growth states, while amplifying scale in existing and/or new markets.

Portfolio consists of top-quality, physician-owned facilities which have generated strong growth and recovery from COVID-19. Comprised of high-quality centers with minimal facility-level debt, the Portfolio includes relatively young facilities with an average age of seven years. The Portfolio has over 800 medical staff physicians and a case mix weighted heavily toward high-growth MSK procedures in a lower cost-of-care setting, with approximately 80 percent attributed to orthopedics, pain and spine.

Cements strategic “partner of choice” reputation for ambulatory development, building on USPI’s 20+-year track record of operational excellence, integration and synergy capture. The Portfolio includes a roster of world-class physician partners, reinforcing USPI’s culture of collaborative development with physicians. USPI has a long history of acquiring, integrating and successfully growing SCD centers together with premier physicians, which provides opportunities for continued expansion of these partnerships. As a leader in terms of quality, relationships and capabilities, the enhanced USPI platform will have close to 5,000 physician partners and over 50 health system partners.

Attractive financial profile with immediate and significant EPS accretion and further EBITDA diversification. Tenet expects thetransaction to generate double-digit returns on invested capital within three years of completion, along with approximately 28 percent accretion to earnings per share in 2021. The transaction will further diversify Tenet’s Adjusted EBITDA with approximately 42 percent expected to be generated by the Company’s ambulatory business in 2021, up significantly from 4 percent in 2014 prior to Tenet’s acquisition of a majority stake in USPI. The Company expects to realize approximately $40 million to $50 million of annual run-rate synergies over the next three years.

Acquisition financed with balance sheet cash. The transaction will be fully funded with cash from Tenet’s balance sheet separate from grant funds that have been received as a result of the Coronavirus Aid, Relief and Economic Security (CARES) Act. In addition, the transaction is expected to be leverage neutral, and Tenet remains committed to continued deleveraging over time.

Goldman Sachs & Co LLC acted as financial advisor to Tenet, and Willkie Farr & Gallagher LLP served as legal counsel.

Management’s Webcast Discussion of the Transaction

Tenet management will discuss this transaction on a webcast scheduled for 8:30 a.m. Eastern Time (7:30 a.m. Central Time) today, Dec. 10, 2020. Investors can access the webcast through the Company’s website at www.tenethealth.com/investors. The slide presentation associated with the webcast referenced above and a copy of this press release are available on the Company’s Investor Relations website. A replay of the webcast will be available on Tenet’s website for approximately 30 days.

Cautionary Statement

This release contains “forward-looking statements” – that is, statements that relate to future, not past, events. In this context, forward-looking statements address our expectations of the benefits and synergies of the acquisition and the performance of the centers in the Portfolio, as well as the Company’s expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “assume,” “believe,” “budget,” “estimate,” “forecast,” “intend,” “plan,” “predict,” “project,” “seek,” “see,” “target,” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain, especially with regards to developments related to COVID-19, and are subject to numerous risks and uncertainties, many of which are outside of our control. Particular uncertainties that could cause the Company’s actual results to be materially different than those expressed in the Company’s forward-looking statements include, but are not limited to, the ability to close and successfully integrate the operations of the acquired centers into our enterprise; the ability to recognize the anticipated benefits of the acquisition, which may be affected by, among other things, competition, regulation, our ability to grow profitably and maintain relationships with physicians and key healthcare system partners; the risk that the acquisition disrupts current plans and operations of our enterprise and/or the acquired centers; the impact of the COVID-19 pandemic and the other factors disclosed under “Forward-Looking Statements” and “Risk Factors” in our Form 10-K for the year ended December 31, 2019, subsequent Form 10-Q filings and other filings with the Securities and Exchange Commission.

About Tenet Healthcare

Tenet Healthcare Corporation (NYSE: THC) is a diversified healthcare services company headquartered in Dallas with 110,000 employees. Through an expansive care network that includes United Surgical Partners International, we operate 65 hospitals and more than 520 other healthcare facilities, including surgical hospitals, ambulatory surgery centers, urgent care and imaging centers and other care sites and clinics. We also operate Conifer Health Solutions, which provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers and other customers. Across the Tenet enterprise, we are united by our mission to deliver quality, compassionate care in the communities we serve. For more information, please visit www.tenethealth.com.

Investor Contact

Regina Nethery


[email protected]

Media Contact

Lesley Bogdanow


[email protected]

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Hospitals Health Surgery Practice Management